Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma Journal Article
| Authors: | Jagannath, S.; Martin, T. G.; Lin, Y.; Cohen, A. D.; Raje, N.; Htut, M.; Deol, A.; Agha, M.; Berdeja, J. G.; Lesokhin, A. M.; Liegel, J. J.; Rossi, A.; Lieberman-Cribbin, A.; Usmani, S. Z.; Dhakal, B.; Parekh, S.; Li, H.; Wang, F.; Montes De Oca, R.; Plaks, V.; Sun, H.; Banerjee, A.; Schecter, J. M.; Lendvai, N.; Madduri, D.; Lengil, T.; Zhu, J.; Koneru, M.; Akram, M.; Patel, N.; Costa Filho, O.; Jakubowiak, A. J.; Voorhees, P. M. |
| Article Title: | Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma |
| Abstract: | CARTITUDE-1 evaluated ciltacabtagene autoleucel (cilta-cel) in patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM). We describe overall survival (OS), ≥5-year progression-free outcomes, associated biomarkers, and safety, with a median study follow-up of 61.3 months. For the 97 treated patients, median OS was 60.7 months (95% CI, 41.9 to not estimable). One third (32/97) of patients remain alive and progression-free for ≥5 years after a single cilta-cel infusion, without maintenance treatment. Twelve of these patients treated at a single center underwent serial minimal residual disease (MRD) and positron emission tomography-computed tomography assessments, and all (100%) were MRD-negative (at least 10-5 threshold) and imaging-negative at year 5 or later after cilta-cel. Baseline characteristics, including the presence of high-risk cytogenetics and extramedullary disease, were generally comparable for the 32 patients who were progression-free for ≥5 years versus patients who had progressive disease by year 5. A trend of lower baseline tumor burden, higher fraction of naïve T-cells in the cilta-cel drug product, higher T cell-to-neutrophil ratio, higher hemoglobin and platelets at baseline, and higher effector-to-target ratio were associated with ≥5-year progression-free status. The safety profile of cilta-cel remained consistent with previous reports. To our knowledge, our data provide the first evidence that cilta-cel is potentially curative in patients with RRMM. © 2025 American Society of Clinical Oncology. |
| Journal Title: | Journal of Clinical Oncology |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-01-01 |
| Start Page: | JCO |
| End Page: | 25 |
| Language: | English |
| DOI: | 10.1200/jco-25-00760 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work